FDA provides update on ongoing investigation into ARB drugs; new losartan recall announced
FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall
Published in FDA News Alerts
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings
- Coronavirus (COVID-19) Update: March 30, 2021
- Bit & Bet LLC Issues Voluntary Nationwide Recall of Thumbs Up 7 Blue 69K Due to Presence of Undeclared Sildenafil and Tadalafil
- Mammography Problems at Tennessee Women’s Care P.C. in Nashville, TN: FDA Safety Communication